Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 3, 1996, Pages 255-264

  Laganière, Sylvie ^a   Davies, Richard F ^a   Carignan, Germain ^a   Foris, Kathy ^a   Goernert, Lynne ^a   Carrier, Karen ^a   Pereira, Conrad ^a   McGilveray, Iain ^a  

^a Bureau of Drug Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM; QUINIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ELECTROCARDIOGRAM; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DILTIAZEM; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; QUINIDINE; REFERENCE VALUES; TIME FACTORS; VASODILATOR AGENTS;

EID: 0029807226     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90052-1     Document Type: Article

References (47)

1. Physician's desk reference. 49th ed. Montvale, NJ: Medical Economics, 1995;1218.
2. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287-95.
3. Ueda CT, Quinidine. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV, editors. Applied pharmacokinetics. 3rd ed. Vancouver, Applied Therapeutics, 1992:1-23.
4. Spinler SA, Cheng JWM, Kindwall KE, Charland SL. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995;57:89-94.
5. Brosen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987;60:312-4.
6. Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 1986;22:739-43.
7. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984;34:73-80.
8. Masubuchi Y, Hosokawa S, Horie T, Ohmori S, Kitada M, Narimatsu S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. Drug Metab Dispos 1994;22:909-15.
9. Yasuhara M, Yatsukzuka A, Yamada K, Okumura K, Hori R, Sakurai T, et al. Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man. J Pharmacobiodyn 1990;13:681-7.
10. Zhou HH, Anthony LB, Roden DM, Wood AJJ. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 1990;47:686-93.
11. Marathe PH, Shen DD, Nelson WL. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Drug Metab Dispos 1994;22:237-47.
12. Leemann T, Dayer P, Meyer UA. Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 1986;29:739-41.
13. Leemann TD, Devi KP, Dayer P. Similar effect of oxidation deficiency and quinidine on the apparent volume of distribution of metoprolol. Eur J Clin Pharmacol 1993;45:65-71.
14. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988;247:242-7.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake inhibitor antidepressants and by quinidine and ketoconazole: a model system to predict drug interaction in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
16. Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 1989;28:29-36.
17. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: influence of genetic polymorphism. J Pharmacol Exper Ther 1989; 249:134-42.
18. Inaba T, Tyndale RE, Mahon WA. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol 1986;22:199-200.
19. Funck-Brentano C, Kroemer HK, Pavlou H, Woosley RL, Roden DM. Genetically determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 1989;27:435-44.
20. Oates NS, Feher MD, Perry HE, Schmid BJ, Sever PS, Idle JR. Influence of quinidine on nifedipine plasma pharmacokinetics [abstract]. Br J Clin Pharmacol 1988;25:675.
21. Turgeon J, Fiset C, Giguere R, Gilbert M, Moerike K, Rouleau JR, et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J Pharmacol Exp Ther 1991;259:789-98.
22. Coutts RT, Bolaji OO, Baker GB. Metabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparation. Drug Metab Dispos 1994;22:756-60.
23. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985;34:2549-53.
24. Buckley MMT, Grant SM, Goa KL, McTavish D, Sorkin EM. diltiazem: a reappraisal of its pharmacological properties and therapeutic use. Drugs 1990;39: 757-806.
25. Kazierad DJ, Lalonde RL, Hoon TJ, Mirvis DM, Bottoroff MB. The effect of diltiazem on the disposition of encainide and its active metabolites. Clin Pharmacol Ther 1989;46:668-73.
26. Hermann DJ, Krol TF, Dukes GE, Aussey EK, Danis M, Han YH, et al. Comparison of verapamil, diltiazem and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol 1992;32:176-83.
27. Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 1990;29:11280-92.
28. Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot JP, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990;18:711-9.
29. Matera MG, De Santis D, Vacca C, Fici F, Romano AR, Marrazo R, et al. Quinidine-diltiazem: pharmacokinetic interaction in humans. Curr Ther Res 1986; 40:653-6.
30. Carignan G, Carrier K, Laganière S, Lessard M. Simultaneous determination of diltiazem and quinidine in human plasma by liquid chromatography. J Chromatogr 1995;672:261-9.
31. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920;7:353.
32. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991;29:323-8.
33. Expert Advisory Committee on Bioavailability, Health Protection Branch. Report C: Report on bioavailability of oral dose formulations, not in modified-release form, of drugs used for systemic effects, having complicated or variable pharmacokinetics. Ottawa, Ontario: Drugs Director HPB, December 1992.
34. Schall R, Hundt HKL, Luus HG. Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies. Int J Clin Pharmacol Ther 1994;32:633-7.
35. Laganière S, McGilveray IJ. Protein binding of drugs. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker, 1995;151-77.
36. Fremstad D, Nilsen OG, Storstein L, Amlie J, Jacobsen S. Pharmacokinetics of quinidine related to plasma protein binding in man. Eur J Clin Pharmacol 1979;15:187-92.
37. Magometschnigg D, Bonelly J, Gassner A, Kaik G, Hitzenberger G. Cardiovascular effect of diltiazem in healthy volunteers. Int J Clin Pharmacol 1981;19: 514-8.
38. Théroux P, Waters DD, Debaisieux JC, Szlacheie J, Mizgala HF, Bourassa MG. Hemodynamic effects of calcium ion antagonists after acute myocardial infarction. Clin Invest Med 1980;3:81-5.
39. van der Wall EE, Cats VM, Blokland JAK, Bosker HA, Arndt JW, Pauwels EKJ, et al. The effects of diltiazem on cardiac function in silent ischemia after myocardial infarction. Am Heart J 1989;118:655-61.
40. Wooding-Scott RA, Smalley J, Visco J, Slaughter RL. The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. Br J Clin Pharmacol 1988;26:415-23.
41. Ochs HR, Greenblatt DJ, Woo E. Clinical pharmacokinetics of quinidine. Clin Pharmacokinet 1980;5: 150-68.
42. Fattinger K, Voseh S, Ha HR, Borner M, Follath F. Population pharmacokinetics of quinidine. Br J Clin Pharmacol 1991;31: 279-86.
43. Saenzcampos D, Bayes MC, Martin S, Barbanoj MJ, Jane F. Gender-related pharmacokinetics of diltiazem in healthy subjects. Int J Clin Pharmacol Ther 1995; 33:397-400.
44. Hermann Ph, Rodger SD, Remones G, Thenot JP, London DR, Morselli PL. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol 1983;24:349-52.
45. Follath F, Ganzinger U, Schuetz E. Reliability of antiarrhythmic drug plasma concentration monitoring. Clin Pharmacokinet 1983;8:63-82.
46. Cremer KF, Pieper JA, Joyal M. Relationship between diltiazem concentrations and hemodynamic responses [abstract]. Clin Pharmacol Ther 1985;37:188.
47. Joyal M, Pieper J, Cremer K, Feldman RL, Pepine CJ. Pharmacodynamic aspects of intravenous diltiazem administration. Am Heart J 1986;111:54-61.